# Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

> **NCT01158105** · PHASE2 · UNKNOWN · sponsor: **Baylor Research Institute** · enrollment: 25 (estimated)

## Conditions studied

- Chronic Graft-versus-host Disease

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT01158105
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-06
- **Primary completion:** 2013-05
- **Final completion:** 2017-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2016-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158105, "Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01158105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*